Last updated: September 8, 2026
The listed ingredients correspond to a polyethylene glycol 3350 electrolyte bowel-preparation kit used before colonoscopy and other lower-gastrointestinal procedures. The formulation is associated with HalfLytely and Bisacodyl Tablets, a prescription bowel-prep product historically marketed by Braintree Laboratories and later associated with Salix Pharmaceuticals and Valeant Pharmaceuticals, now Bausch Health.
The product has limited standalone financial visibility because manufacturers generally report revenue by business segment rather than by individual bowel-preparation kit. Its commercial trajectory is defined by generic substitution, low-cost electrolyte solutions, procedure volumes, and competition from newer low-volume products such as SUTAB and SUPREP.
What drug contains bisacodyl, polyethylene glycol 3350, potassium chloride, sodium bicarbonate and sodium chloride?
The combination is a two-part bowel-preparation regimen:
| Component |
Function |
| Polyethylene glycol 3350 |
Osmotic laxative that retains water in the bowel |
| Sodium chloride |
Replaces sodium and chloride ions |
| Potassium chloride |
Replaces potassium |
| Sodium bicarbonate |
Provides bicarbonate and helps maintain electrolyte balance |
| Bisacodyl |
Stimulant laxative used to initiate or accelerate bowel evacuation |
HalfLytely paired an oral bisacodyl tablet with a PEG 3350 electrolyte solution. The formulation was designed to reduce the volume of PEG solution required compared with older 4-liter lavage products.
The product belongs to the prescription bowel-preparation market, not the chronic constipation market. MiraLAX, which contains PEG 3350 without the electrolyte and bisacodyl components, is a separate product and should not be treated as the same drug.
What is the FDA status of HalfLytely and Bisacodyl Tablets?
HalfLytely and Bisacodyl Tablets was approved in the United States under NDA 021881. FDA records identify the product as a prescription bowel-preparation product containing PEG 3350 and electrolytes with bisacodyl tablets.[1]
The product is no longer a major branded growth asset. FDA’s Drugs@FDA and labeling records should be used to distinguish approval history from current commercial availability. An approved NDA can remain in regulatory records even after a product is discontinued or no longer actively promoted.
| Regulatory issue |
Assessment |
| FDA pathway |
New drug application for bowel preparation |
| Dosage form |
Oral PEG electrolyte solution plus bisacodyl tablets |
| Primary use |
Colonoscopy and lower-gastrointestinal diagnostic preparation |
| Current commercial position |
Mature or discontinued branded product |
| Prescription status |
Prescription bowel-preparation category |
| Regulatory substitute |
Generic PEG-electrolyte solutions and competing branded preparations |
The commercial question is no longer whether the formulation can obtain market authorization. The relevant question is whether a manufacturer can sell it profitably against generic PEG-electrolyte products and newer lower-volume regimens.
When does this bowel-preparation product lose exclusivity?
The primary U.S. exclusivity risk arose from the age of the formulation and the availability of alternative PEG-electrolyte products. Patent exclusivity is not the main commercial barrier.
The product’s commercial protection has likely been weakened by four factors:
- The active ingredients are old and widely used.
- PEG electrolyte bowel-preparation formulations have extensive generic precedent.
- The product’s clinical differentiation is limited to dosing convenience and the use of bisacodyl.
- Colonoscopy centers frequently use formularies, substitution protocols, and payer-driven product selection.
The exact patent estate for HalfLytely is less important than the absence of meaningful composition-of-matter protection. PEG 3350, sodium chloride, potassium chloride, and sodium bicarbonate are established ingredients. Any remaining protection would more likely relate to formulation, preparation instructions, packaging, dosing sequence, or method-of-use claims.
What patents protect PEG 3350 electrolyte bowel preparations?
PEG 3350 electrolyte bowel preparations generally rely on regulatory approval, manufacturing know-how, trademarks, and limited formulation claims rather than strong active-ingredient patents.
Potential protection categories include:
| Protection category |
Commercial relevance |
| Composition patents |
Weak for old electrolyte ingredients |
| Formulation patents |
Possible protection for concentration, stability, flavoring, or reconstitution |
| Method-of-use patents |
Possible protection for split dosing or administration protocols |
| Packaging patents |
Relevant to kits containing tablets and powder |
| Manufacturing know-how |
Important for uniformity, stability, dissolution, and flavor |
| Trademarks |
Relevant to brand recognition but weak against generic substitution |
| Regulatory exclusivity |
Generally limited for mature formulations |
For this ingredient combination, the principal IP risk is not a high-value patent cliff comparable to a biologic or protected small-molecule therapy. The more important barrier is operational: producing a stable, palatable, compliant preparation at a low cost.
How strong is the patent estate for bisacodyl and PEG 3350 electrolyte products?
The patent estate is weak to moderate from a commercial-defense perspective.
Composition-of-matter protection
There is no meaningful new-molecule protection for the listed ingredients. PEG 3350 and the electrolytes are longstanding pharmaceutical ingredients. Bisacodyl is also an established stimulant laxative.
Formulation protection
Formulation claims may cover:
- Electrolyte concentrations
- PEG molecular-weight specifications
- Flavor systems
- Powder reconstitution characteristics
- Stability during storage
- Bisacodyl tablet packaging
- Reduced-volume administration
These claims can create litigation leverage if drafted narrowly, but they rarely prevent broad generic competition across the category.
Method-of-use protection
Method-of-use claims may address:
- Split-dose administration
- Timing before colonoscopy
- Use with a stimulant laxative
- Administration with reduced fluid volume
The practical enforceability of these claims is limited when physicians and patients can use alternative bowel-preparation products for the same procedure.
Which companies compete with this bowel-preparation formulation?
The market is divided between high-volume PEG-electrolyte solutions, lower-volume sulfate-based products, tablet-based preparations, and sodium picosulfate products.
| Product |
Main company or marketing group |
Formulation type |
Competitive position |
| GoLYTELY |
Viatris and authorized generic suppliers |
PEG 3350 with electrolytes |
Large-volume, established generic market |
| NuLYTELY |
Generic and legacy manufacturers |
PEG electrolyte solution |
Mature, price-sensitive segment |
| TriLyte |
Generic and legacy manufacturers |
PEG electrolyte solution |
Institutional and generic use |
| SUPREP |
Braintree/Salix, Bausch Health |
Sodium sulfate-based solution |
Lower-volume branded competitor |
| SUTAB |
Sebela Pharmaceuticals |
Oral sulfate tablets |
Tablet-based premium competitor |
| Clenpiq |
Ferring Pharmaceuticals |
Sodium picosulfate, magnesium oxide and citric acid |
Low-volume liquid competitor |
| MiraLAX-based regimens |
OTC PEG 3350 suppliers |
PEG 3350 without standard electrolytes |
Off-label or protocol-specific alternative |
SUTAB has a different commercial profile because tablet-based administration can command a higher price than generic liquid PEG solutions. SUPREP and Clenpiq compete on reduced liquid volume and patient convenience. Traditional PEG electrolyte products compete primarily on safety familiarity, hospital adoption, and low acquisition cost.
What is the financial trajectory of the product category?
The financial trajectory is mature, low-growth, and fragmented.
Revenue drivers
The main volume driver is the number of colonoscopies and other procedures requiring bowel cleansing. Demand is therefore linked to:
- Screening colonoscopy volumes
- Gastrointestinal disease diagnosis
- Follow-up procedures
- Hospital and ambulatory surgery center activity
- Population aging
- Insurance coverage and preventive-care utilization
The category does not benefit from chronic daily use. A patient typically uses the product once per procedure, which limits lifetime revenue per patient.
Pricing dynamics
Generic PEG-electrolyte solutions exert downward pressure on pricing. Branded products can preserve higher prices only if they demonstrate a clear advantage in:
- Lower liquid volume
- Better tolerability
- Fewer administration steps
- Improved cleansing quality
- Reduced nausea and vomiting
- Greater patient adherence
- Better operational efficiency for endoscopy centers
Products without a strong convenience advantage face rapid price compression after generic entry.
Manufacturer economics
The product is inexpensive to manufacture relative to patented pharmaceuticals. However, margins can still be affected by:
- Powder blending and electrolyte uniformity
- Sachet and bottle packaging
- Flavoring systems
- Tablet co-packaging
- Supply-chain costs
- Contract manufacturing
- FDA quality requirements
- Product recalls or shortages
A kit containing bisacodyl tablets creates more packaging and quality-control requirements than a single powder product. Those costs are manageable but reduce the advantage of competing solely on price.
Are there Paragraph IV challenges for this product?
Paragraph IV litigation is not the central current risk for the listed combination. Paragraph IV filings matter when a generic applicant challenges a listed patent for an active branded product. For an old PEG-electrolyte bowel-preparation kit, the commercial exposure is more likely to arise from ordinary generic competition, abbreviated new drug applications, and products that use a different formulation.
The key distinctions are:
| Challenge type |
Relevance |
| Paragraph IV certification |
Relevant if an active Orange Book patent remains listed |
| Section viii carve-out |
Possible for method-of-use claims |
| ANDA approval |
Core pathway for generic PEG-electrolyte products |
| 505(b)(2) application |
Relevant for modified bowel-prep formulations |
| Therapeutic substitution |
Common commercial threat even without patent litigation |
A generic applicant may avoid some method-of-use claims by labeling out a protected indication or dosing instruction. Because bowel-preparation products have overlapping clinical uses, such carve-outs may reduce the practical value of remaining patents.
What is the Orange Book status of the formulation?
The Orange Book status depends on whether the NDA remains active and whether patents are currently listed. Historical approval does not establish an active commercial listing or enforceable patent position.
For financial analysis, the relevant Orange Book questions are:
- Is NDA 021881 listed as active or discontinued?
- Are any patents currently listed against the NDA?
- Do listed patents cover the formulation, method of use, packaging, or dosing regimen?
- Are generic approvals therapeutically equivalent or merely substitutable alternatives?
- Has the FDA approved an authorized generic or competing 505(b)(2) product?
FDA’s Orange Book and Drugs@FDA databases are the controlling sources for current listing and patent status.[1,2]
What generic entry risks exist?
Generic entry risk is high because the product has:
- Old active ingredients
- Limited composition-of-matter protection
- Multiple established generic competitors
- Low switching costs for prescribers
- Strong payer incentives to use low-cost alternatives
- Limited differentiation from other PEG-based bowel preparations
The principal launch scenarios are:
Scenario 1: Generic PEG-electrolyte substitution
This is the most likely commercial outcome. Generic suppliers compete for pharmacy, hospital, and ambulatory surgery center contracts. Prices decline as more suppliers enter.
Scenario 2: Premium tablet displacement
SUTAB and similar products can take share where patients or clinicians prioritize reduced liquid volume. This does not directly restore the economics of HalfLytely, because the tablet product has a different formulation and brand strategy.
Scenario 3: Institutional formulary consolidation
Hospitals may select one or two preferred bowel preparations. A mature PEG-electrolyte product can retain volume through formulary contracts even when its price is low.
Scenario 4: Brand withdrawal
If net pricing falls below the cost of production, packaging, regulatory maintenance, and distribution, a manufacturer may discontinue the branded or lightly differentiated kit.
How does this product compare with SUTAB and SUPREP?
| Metric |
PEG 3350/electrolyte plus bisacodyl |
SUPREP |
SUTAB |
| Core formulation |
PEG 3350, electrolytes and bisacodyl |
Sulfate-based liquid |
Sulfate-based tablets |
| Liquid burden |
Higher than tablet regimens |
Lower than traditional PEG |
Low liquid volume, but requires many tablets and water |
| Pricing |
Generic or low-cost |
Branded |
Branded premium |
| Patent strength |
Limited |
More relevant formulation and brand protection |
More relevant formulation and brand protection |
| Main buyer |
Hospitals, payers, cost-sensitive systems |
Physicians and patients seeking lower volume |
Patients prioritizing tablet administration |
| Growth profile |
Mature or declining |
Branded competitive |
Growth or share-taking potential |
| Main weakness |
Taste and volume |
Electrolyte and tolerability considerations |
Tablet burden and cost |
The listed PEG combination is structurally disadvantaged against tablet products on convenience and against generic PEG solutions on price.
What licensing deals and litigation affect the market?
The historical commercial rights to HalfLytely were connected to Braintree Laboratories and later Salix Pharmaceuticals. Salix became part of Valeant Pharmaceuticals in 2015, and Valeant later changed its corporate name to Bausch Health Companies.[3]
Current market value is more likely to reside in active brands such as SUPREP than in the older HalfLytely formulation. Licensing, co-promotion, and distribution agreements may affect individual products, but they do not materially strengthen the underlying patent estate for the listed ingredients.
No major current litigation event should be assumed solely from the ingredient list. Litigation analysis must be tied to a specific NDA, patent number, defendant, and jurisdiction. The commercial risks here are primarily substitution, pricing, and product availability rather than high-value patent enforcement.
What is the geographic market outlook?
The United States is the most commercially significant market for these prescription bowel preparations because of its large colonoscopy volume and branded-product market.
| Region |
Market characteristics |
| United States |
Mix of generic PEG products and branded low-volume preparations |
| Europe |
National reimbursement and hospital procurement influence product selection |
| Japan |
Procedure protocols and local regulatory requirements shape demand |
| China |
Growing diagnostic volumes, with local manufacturers and price sensitivity |
| Emerging markets |
Lower branded pricing and greater reliance on basic laxative regimens |
U.S. exclusivity and Orange Book analysis do not determine market rights in Europe, Canada, Japan, or China. Each jurisdiction requires separate review of formulation patents, regulatory approvals, trademarks, and local generic registrations.
Key Takeaways
- The listed ingredients describe a PEG 3350 electrolyte bowel-preparation kit used with bisacodyl.
- The formulation is associated with HalfLytely and Bisacodyl Tablets, a mature product with limited current commercial importance.
- Composition-of-matter patent protection is weak because all ingredients are established.
- Formulation, dosing, packaging, and method-of-use claims may exist but provide limited durable protection.
- Generic PEG-electrolyte products create high price pressure.
- SUTAB, SUPREP, and Clenpiq compete through lower liquid volume, tablet administration, or improved convenience.
- Financial performance is driven by procedure volumes and formulary access, not repeat chronic use.
- The highest-probability commercial outcome is continued generic substitution and declining branded relevance.
- The current market opportunity is stronger for differentiated low-volume or tablet-based bowel preparations than for traditional PEG-electrolyte kits.
FAQs
Is HalfLytely the same as MiraLAX?
No. HalfLytely used PEG 3350 with electrolytes and a bisacodyl tablet. MiraLAX contains PEG 3350 without the electrolyte mixture and is marketed primarily for constipation.
Is this formulation a biologic or biosimilar product?
No. It is a conventional small-molecule and polymer-based drug product. Biosimilar rules do not apply.
Can a generic manufacturer copy the exact formulation?
A generic manufacturer can seek FDA approval through an ANDA if it meets applicable sameness, quality, bioequivalence, labeling, and manufacturing requirements. It may also pursue a different formulation through another regulatory pathway.
Does bisacodyl create meaningful patent protection?
No. Bisacodyl is an established active ingredient. Its inclusion may support a particular combination or dosing claim, but it does not provide new-molecule exclusivity.
What product has the strongest commercial position in this category?
The answer depends on the segment. Generic PEG-electrolyte products are strongest on cost and institutional use. SUTAB and SUPREP are stronger in branded, lower-volume segments where convenience supports premium pricing.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- Bausch Health Companies Inc. (2015). Annual report and corporate transaction disclosures. https://ir.bauschhealth.com/
